Product Code: PMRREP28603
Report Scope
The latest publication by Persistence Market Research on the global pet allergy treatment market evaluates the opportunities and current market landscape and provides detailed analysis, and updates about corresponding sections affecting the market. The study offers detailed insights into current market dynamics, which include the drivers, restraints, trends, and opportunities in the market. The principal aim of the market study is to present exclusive information about how the market will perform during the forecast period of 2023 to 2033.
Important indicators for the successful growth of the pet allergy treatment market are presented in this comprehensive report, which includes a Year-on-Year (Y-o-Y) growth analysis of the market, and compounded annual growth rate (CAGR), which are described exhaustively in Persistence Market Research's study. This research study can support readers to know the demand for pet allergy treatment products and the quantitative development opportunities during the study period.
The research is beneficial for shareholders in the landscape, including investors, manufacturers, service providers, distributors, and suppliers, and can help them in developing suitable business strategies to flourish in the pet allergy treatment market. Shareholders in the pet allergy treatment market, industry experts, investors, researchers, and reporters, as well as business enthusiasts, can leverage insights and information presented in this Persistence Market Research study.
Market statistics, as well as information linked to the macro- as well as macroeconomic variables affecting the business scenario in the pet allergy treatment market, are also included in the current study. Depending on potential developments in the market, substantive insights are also encountered in this report. Additionally, by the data submitted in this report, minor companies and new entrants in the industry can be aided in making suitable company choices to achieve traction in the market.
Key Market Segments
Persistence Market Research's study on the pet allergy treatment market offers information divided into six important segments - drug class, indication, pet type, route of administration, distribution channel, and region. This report offers comprehensive data and information about the important market dynamics and growth parameters associated with these categorAttribute
Attribute Details
Drug Class:
- Antihistamines
- Corticosteroids
- Immunotherapy
- Antibiotics
Indication:
- Allergic Dermatitis
- Food Allergy
- Fleabite Allergy
- Contact Allergy
Pet Type:
- Dogs
- Cats
- Rodents & Rabbits
Route of Administration:
Distribution Channel:
- Veterinary Hospitals
- Retail Pharmacies
- Online Pharmacies
- Others
Region:
- North America
- Latin America
- Europe
- South Asia
- East Asia
- Oceania
- Middle East and Africa (MEA)
Key Questions Answered in Report:
- Which regions will continue to remain the most profitable markets for pet allergy treatment over the coming years?
- How will changing trends influence the market?
- How can market players capture the low-hanging opportunities in developed regions?
- What are the strategies of stakeholders in the market to shape their position in this landscape?
- What are the restraining factors that investors need to be aware of and might tackle while investing in the market?
- What are the developmental trends that will influence the market?
- How can companies in the pet allergy treatment market avail themselves of the growth opportunities in developed and emerging sectors?
Research Methodology
In Persistence Market Research's study, a unique research methodology is utilized to conduct extensive research on the growth of the pet allergy treatment market, and reach conclusions on the future growth parameters of the market. This research methodology is a combination of primary and secondary research, which helps analysts to ensure the accuracy and reliability of the conclusions.
Secondary resources referred to by analysts during the production of the market study include statistics from governmental organizations, trade journals, white papers, and internal and external proprietary databases. Analysts have interviewed senior managers, product portfolio managers, CEOs, VPs, marketing/product managers, and market intelligence managers, who contributed to the development of this report as a primary resource.
Comprehensive information acquired from primary and secondary resources acts as validation from companies in the market and makes Persistence Market Research's projections on the growth prospects of the pet allergy treatment market is more accurate and reliable.
Table of Contents
1. Executive Summary
- 1.1. Global Market Outlook
- 1.2. Demand-side Trends
- 1.3. Supply-side Trends
- 1.4. Analysis and Recommendations
2. Market Overview
- 2.1. Market Coverage / Taxonomy
- 2.2. Market Definition / Scope / Limitations
- 2.3. Inclusions and Exclusions
3. Key Market Trends
- 3.1. Key Trends Impacting the Market
- 3.2. Product Innovation / Development Trends
4. Value Added Insights
- 4.1. Product Adoption Analysis
- 4.2. Product USPs/Features Analysis, By Brands
- 4.3. Regulatory Landscape, By Country
- 4.4. Recent Product Approval/Launches
- 4.5. Disease Epidemiology
- 4.6. Porter's Analysis
- 4.7. PESTLE Analysis
- 4.8. Value Chain Analysis
- 4.9. Unmet Needs
5. Market Background
- 5.1. Macro-Economic Factors
- 5.1.1. Global Healthcare Expenditure Outlook
- 5.1.2. Global Pharmaceutical Market Outlook
- 5.1.3. Global Animal Healthcare Market Outlook
- 5.2. Forecast Factors - Relevance & Impact
- 5.2.1. Rising Rate of Pet Adoption
- 5.2.2. Increase in Research and Development
- 5.2.3. Strategic Collaborations among players
- 5.2.4. Cost of Product
- 5.2.5. Business Expansions
- 5.2.6. Frequency of Product Approval
- 5.2.7. Pet Care Insurance
- 5.3. Market Dynamics
- 5.3.1. Drivers
- 5.3.2. Restraints
- 5.3.3. Opportunity Analysis
6. Global Market Demand (in Value or Size in US$ Million) Analysis 2017 to 2022 and Forecast, 2023 to 2033
- 6.1. Historical Market Value (US$ Million) Analysis, 2017 to 2022
- 6.2. Current and Future Market Size (US$ Million) Projections, 2023 to 2033
- 6.2.1. Y-o-Y Growth Trend Analysis
- 6.2.2. Absolute $ Opportunity Analysis
- 6.3. Revenue Opportunity Scenario- Likely/Conservative/Optimistic
7. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Drug Class
- 7.1. Introduction / Key Findings
- 7.2. Historical Market Size (US$ Million) Analysis By Drug Class, 2017 to 2022
- 7.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
- 7.3.1. Antihistamines
- 7.3.2. Corticosteroids
- 7.3.3. Immunotherapy
- 7.3.4. Antibiotics
- 7.4. Market Attractiveness Analysis By Drug Class
8. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Indication
- 8.1. Introduction / Key Findings
- 8.2. Historical Market Size (US$ Million) Analysis By Indication, 2017 to 2022
- 8.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Indication, 2023 to 2033
- 8.3.1. Allergic Dermatitis
- 8.3.2. Food Allergy
- 8.3.3. Fleabite Allergy
- 8.3.4. Contact Allergy
- 8.4. Market Attractiveness Analysis By Indication
9. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Pet Type
- 9.1. Introduction / Key Findings
- 9.2. Historical Market Size (US$ Million) Analysis By Pet Type, 2017 to 2022
- 9.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Pet Type, 2023 to 2033
- 9.3.1. Dogs
- 9.3.2. Cats
- 9.3.3. Rodents and rabbits
- 9.4. Market Attractiveness Analysis By Pet Type
10. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Route of Administration
- 10.1. Introduction / Key Findings
- 10.2. Historical Market Size (US$ Million) Analysis By Route of Administration, 2017 to 2022
- 10.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Route of Administration, 2023 to 2033
- 10.3.1. Oral
- 10.3.2. Injectable
- 10.3.3. Topical
- 10.4. Market Attractiveness Analysis By Route of Administration
11. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, By Distribution Channel
- 11.1. Introduction / Key Findings
- 11.2. Historical Market Size (US$ Million) Analysis By Distribution Channel, 2017 to 2022
- 11.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033
- 11.3.1. Veterinary Hospitals
- 11.3.2. Retail Pharmacies
- 11.3.3. Online Pharmacies
- 11.3.4. Others
- 11.4. Market Attractiveness Analysis By Distribution Channel
12. Global Market Analysis 2017 to 2022 and Forecast 2023 to 2033, by Region
- 12.1. Introduction / Key Findings
- 12.2. Historical Market Size (US$ Million) Analysis By Region, 2017 to 2022
- 12.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Region, 2023 to 2033
- 12.3.1. North America
- 12.3.2. Latin America
- 12.3.3. Europe
- 12.3.4. South Asia
- 12.3.5. East Asia
- 12.3.6. Oceania
- 12.3.7. Middle East and Africa
- 12.4. Market Attractiveness Analysis By Region
13. North America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
- 13.1. Introduction / Key Findings
- 13.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2017 to 2022
- 13.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
- 13.3.1. By Country
- 13.3.1.1. United States
- 13.3.1.2. Canada
- 13.3.2. By Drug Class
- 13.3.3. By Indication
- 13.3.4. By Pet Type
- 13.3.5. By Route of Administration
- 13.3.6. By Distribution Channel
- 13.4. Market Attractiveness Analysis By Region
- 13.4.1. By Country
- 13.4.2. By Drug Class
- 13.4.3. By Indication
- 13.4.4. By Pet Type
- 13.4.5. By Route of Administration
- 13.4.6. By Distribution Channel
- 13.5. Market trends
- 13.6. Key Market Participants - Intensity Mapping
- 13.7. Drivers and Restraints - Impact Analysis
- 13.8. Country Level Analysis & Forecast
- 13.8.1. United States Market Analysis
- 13.8.1.1. Introduction
- 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.1.2.1. By Drug Class
- 13.8.1.2.2. By Indication
- 13.8.1.2.3. By Pet Type
- 13.8.1.2.4. By Route of Administration
- 13.8.1.2.5. By Distribution Channel
- 13.8.2. Canada Market Analysis
- 13.8.2.1. Introduction
- 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 13.8.2.2.1. By Drug Class
- 13.8.2.2.2. By Indication
- 13.8.2.2.3. By Pet Type
- 13.8.2.2.4. By Route of Administration
- 13.8.2.2.5. By Distribution Channel
14. Latin America Market Analysis 2017 to 2022 and Forecast 2023 to 2033
- 14.1. Introduction / Key Findings
- 14.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2017 to 2022
- 14.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
- 14.3.1. By Country
- 14.3.1.1. Brazil
- 14.3.1.2. Mexico
- 14.3.1.3. Argentina
- 14.3.1.4. Rest of Latin America
- 14.3.2. By Drug Class
- 14.3.3. By Indication
- 14.3.4. By Pet Type
- 14.3.5. By Route of Administration
- 14.3.6. By Distribution Channel
- 14.4. Market Attractiveness Analysis By Region
- 14.4.1. By Country
- 14.4.2. By Drug Class
- 14.4.3. By Indication
- 14.4.4. By Pet Type
- 14.4.5. By Route of Administration
- 14.4.6. By Distribution Channel
- 14.5. Market trends
- 14.6. Key Market Participants - Intensity Mapping
- 14.7. Drivers and Restraints - Impact Analysis
- 14.8. Country Level Analysis & Forecast
- 14.8.1. Brazil Market Analysis
- 14.8.1.1. Introduction
- 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.1.2.1. By Drug Class
- 14.8.1.2.2. By Indication
- 14.8.1.2.3. By Pet Type
- 14.8.1.2.4. By Route of Administration
- 14.8.1.2.5. By Distribution Channel
- 14.8.2. Mexico Market Analysis
- 14.8.2.1. Introduction
- 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.2.2.1. By Drug Class
- 14.8.2.2.2. By Indication
- 14.8.2.2.3. By Pet Type
- 14.8.2.2.4. By Route of Administration
- 14.8.2.2.5. By Distribution Channel
- 14.8.3. Argentina Market Analysis
- 14.8.3.1. Introduction
- 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 14.8.3.2.1. By Drug Class
- 14.8.3.2.2. By Indication
- 14.8.3.2.3. By Pet Type
- 14.8.3.2.4. By Route of Administration
- 14.8.3.2.5. By Distribution Channel
15. Europe Market Analysis 2017 to 2022 and Forecast 2023 to 2033
- 15.1. Introduction / Key Findings
- 15.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2017 to 2022
- 15.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
- 15.3.1. By Country
- 15.3.1.1. Germany
- 15.3.1.2. France
- 15.3.1.3. Spain
- 15.3.1.4. Russia
- 15.3.1.5. Italy
- 15.3.1.6. BENELUX
- 15.3.1.7. United Kingdom
- 15.3.1.8. Rest of Europe
- 15.3.2. By Drug Class
- 15.3.3. By Indication
- 15.3.4. By Pet Type
- 15.3.5. By Route of Administration
- 15.3.6. By Distribution Channel
- 15.4. Market Attractiveness Analysis By Region
- 15.4.1. By Country
- 15.4.2. By Drug Class
- 15.4.3. By Indication
- 15.4.4. By Pet Type
- 15.4.5. By Route of Administration
- 15.4.6. By Distribution Channel
- 15.5. Market trends
- 15.6. Key Market Participants - Intensity Mapping
- 15.7. Drivers and Restraints - Impact Analysis
- 15.8. Country Level Analysis & Forecast
- 15.8.1. Germany Market Analysis
- 15.8.1.1. Introduction
- 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.1.2.1. By Drug Class
- 15.8.1.2.2. By Indication
- 15.8.1.2.3. By Pet Type
- 15.8.1.2.4. By Route of Administration
- 15.8.1.2.5. By Distribution Channel
- 15.8.2. France Market Analysis
- 15.8.2.1. Introduction
- 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.2.2.1. By Drug Class
- 15.8.2.2.2. By Indication
- 15.8.2.2.3. By Pet Type
- 15.8.2.2.4. By Route of Administration
- 15.8.2.2.5. By Distribution Channel
- 15.8.3. Spain Market Analysis
- 15.8.3.1. Introduction
- 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.3.2.1. By Drug Class
- 15.8.3.2.2. By Indication
- 15.8.3.2.3. By Pet Type
- 15.8.3.2.4. By Route of Administration
- 15.8.3.2.5. By Distribution Channel
- 15.8.4. Russia Market Analysis
- 15.8.4.1. Introduction
- 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.4.2.1. By Drug Class
- 15.8.4.2.2. By Indication
- 15.8.4.2.3. By Pet Type
- 15.8.4.2.4. By Route of Administration
- 15.8.4.2.5. By Distribution Channel
- 15.8.5. Italy Market Analysis
- 15.8.5.1. Introduction
- 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.5.2.1. By Drug Class
- 15.8.5.2.2. By Indication
- 15.8.5.2.3. By Pet Type
- 15.8.5.2.4. By Route of Administration
- 15.8.5.2.5. By Distribution Channel
- 15.8.6. BENELUX Market Analysis
- 15.8.6.1. Introduction
- 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.6.2.1. By Drug Class
- 15.8.6.2.2. By Indication
- 15.8.6.2.3. By Pet Type
- 15.8.6.2.4. By Route of Administration
- 15.8.6.2.5. By Distribution Channel
- 15.8.7. United Kingdom Market Analysis
- 15.8.7.1. Introduction
- 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
- 15.8.7.2.1. By Drug Class
- 15.8.7.2.2. By Indication
- 15.8.7.2.3. By Pet Type
- 15.8.7.2.4. By Route of Administration
- 15.8.7.2.5. By Distribution Channel
16. East Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
- 16.1. Introduction / Key Findings
- 16.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2017 to 2022
- 16.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
- 16.3.1. By Country
- 16.3.1.1. China
- 16.3.1.2. Japan
- 16.3.1.3. South Korea
- 16.3.2. By Drug Class
- 16.3.3. By Indication
- 16.3.4. By Pet Type
- 16.3.5. By Route of Administration
- 16.3.6. By Distribution Channel
- 16.4. Market Attractiveness Analysis By Region
- 16.4.1. By Country
- 16.4.2. By Drug Class
- 16.4.3. By Indication
- 16.4.4. By Pet Type
- 16.4.5. By Route of Administration
- 16.4.6. By Distribution Channel
- 16.5. Market trends
- 16.6. Key Market Participants - Intensity Mapping
- 16.7. Drivers and Restraints - Impact Analysis
- 16.8. Country Level Analysis & Forecast
- 16.8.1. China Market Analysis
- 16.8.1.1. Introduction
- 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.1.2.1. By Drug Class
- 16.8.1.2.2. By Indication
- 16.8.1.2.3. By Pet Type
- 16.8.1.2.4. By Route of Administration
- 16.8.1.2.5. By Distribution Channel
- 16.8.2. Japan Market Analysis
- 16.8.2.1. Introduction
- 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.2.2.1. By Drug Class
- 16.8.2.2.2. By Indication
- 16.8.2.2.3. By Pet Type
- 16.8.2.2.4. By Route of Administration
- 16.8.2.2.5. By Distribution Channel
- 16.8.3. South Korea Market Analysis
- 16.8.3.1. Introduction
- 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 16.8.3.2.1. By Drug Class
- 16.8.3.2.2. By Indication
- 16.8.3.2.3. By Pet Type
- 16.8.3.2.4. By Route of Administration
- 16.8.3.2.5. By Distribution Channel
17. South Asia Market Analysis 2017 to 2022 and Forecast 2023 to 2033
- 17.1. Introduction / Key Findings
- 17.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2017 to 2022
- 17.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
- 17.3.1. By Country
- 17.3.1.1. India
- 17.3.1.2. Indonesia
- 17.3.1.3. Thailand
- 17.3.1.4. Philippines
- 17.3.1.5. Malaysia
- 17.3.1.6. Vietnam
- 17.3.1.7. Rest of South Asia
- 17.3.2. By Drug Class
- 17.3.3. By Indication
- 17.3.4. By Pet Type
- 17.3.5. By Route of Administration
- 17.3.6. By Distribution Channel
- 17.4. Market Attractiveness Analysis By Region
- 17.4.1. By Country
- 17.4.2. By Drug Class
- 17.4.3. By Indication
- 17.4.4. By Pet Type
- 17.4.5. By Route of Administration
- 17.4.6. By Distribution Channel
- 17.5. Market trends
- 17.6. Key Market Participants - Intensity Mapping
- 17.7. Drivers and Restraints - Impact Analysis
- 17.8. Country Level Analysis & Forecast
- 17.8.1. India Market Analysis
- 17.8.1.1. Introduction
- 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.1.2.1. By Drug Class
- 17.8.1.2.2. By Indication
- 17.8.1.2.3. By Pet Type
- 17.8.1.2.4. By Route of Administration
- 17.8.1.2.5. By Distribution Channel
- 17.8.2. Indonesia Market Analysis
- 17.8.2.1. Introduction
- 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.2.2.1. By Drug Class
- 17.8.2.2.2. By Indication
- 17.8.2.2.3. By Pet Type
- 17.8.2.2.4. By Route of Administration
- 17.8.2.2.5. By Distribution Channel
- 17.8.3. Thailand Market Analysis
- 17.8.3.1. Introduction
- 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.3.2.1. By Drug Class
- 17.8.3.2.2. By Indication
- 17.8.3.2.3. By Pet Type
- 17.8.3.2.4. By Route of Administration
- 17.8.3.2.5. By Distribution Channel
- 17.8.4. Philippines Market Analysis
- 17.8.4.1. Introduction
- 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.4.2.1. By Drug Class
- 17.8.4.2.2. By Indication
- 17.8.4.2.3. By Pet Type
- 17.8.4.2.4. By Route of Administration
- 17.8.4.2.5. By Distribution Channel
- 17.8.5. Malaysia Market Analysis
- 17.8.5.1. Introduction
- 17.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.5.2.1. By Drug Class
- 17.8.5.2.2. By Indication
- 17.8.5.2.3. By Pet Type
- 17.8.5.2.4. By Route of Administration
- 17.8.5.2.5. By Distribution Channel
- 17.8.6. Vietnam Market Analysis
- 17.8.6.1. Introduction
- 17.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 17.8.6.2.1. By Drug Class
- 17.8.6.2.2. By Indication
- 17.8.6.2.3. By Pet Type
- 17.8.6.2.4. By Route of Administration
- 17.8.6.2.5. By Distribution Channel
18. Oceania Market Analysis 2017 to 2022 and Forecast 2023 to 2033
- 18.1. Introduction / Key Findings
- 18.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2017 to 2022
- 18.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
- 18.3.1. By Country
- 18.3.1.1. Australia
- 18.3.1.2. New Zealand
- 18.3.2. By Drug Class
- 18.3.3. By Indication
- 18.3.4. By Pet Type
- 18.3.5. By Route of Administration
- 18.3.6. By Distribution Channel
- 18.4. Market Attractiveness Analysis By Region
- 18.4.1. By Country
- 18.4.2. By Drug Class
- 18.4.3. By Indication
- 18.4.4. By Pet Type
- 18.4.5. By Route of Administration
- 18.4.6. By Distribution Channel
- 18.5. Market trends
- 18.6. Key Market Participants - Intensity Mapping
- 18.7. Drivers and Restraints - Impact Analysis
- 18.8. Country Level Analysis & Forecast
- 18.8.1. Australia Market Analysis
- 18.8.1.1. Introduction
- 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 18.8.1.2.1. By Drug Class
- 18.8.1.2.2. By Indication
- 18.8.1.2.3. By Pet Type
- 18.8.1.2.4. By Route of Administration
- 18.8.1.2.5. By Distribution Channel
- 18.8.2. New Zealand Market Analysis
- 18.8.2.1. Introduction
- 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 18.8.2.2.1. By Drug Class
- 18.8.2.2.2. By Indication
- 18.8.2.2.3. By Pet Type
- 18.8.2.2.4. By Route of Administration
- 18.8.2.2.5. By Distribution Channel
19. Middle East and Africa Market Analysis 2017 to 2022 and Forecast 2023 to 2033
- 19.1. Introduction / Key Findings
- 19.2. Historical Market Size (US$ Million) Analysis, By Market Taxonomy, 2017 to 2022
- 19.3. Current and Future Market Size (US$ Million) Analysis and Forecast By Market Taxonomy, 2023 to 2033
- 19.3.1. By Country
- 19.3.1.1. GCC Countries
- 19.3.1.2. Turkiye
- 19.3.1.3. Egypt
- 19.3.1.4. Israel
- 19.3.1.5. South Africa
- 19.3.1.6. Northern Africa
- 19.3.1.7. Rest of Middle East and Africa
- 19.3.2. By Drug Class
- 19.3.3. By Indication
- 19.3.4. By Pet Type
- 19.3.5. By Route of Administration
- 19.3.6. By Distribution Channel
- 19.4. Market Attractiveness Analysis By Region
- 19.4.1. By Country
- 19.4.2. By Drug Class
- 19.4.3. By Indication
- 19.4.4. By Pet Type
- 19.4.5. By Route of Administration
- 19.4.6. By Distribution Channel
- 19.5. Market trends
- 19.6. Key Market Participants - Intensity Mapping
- 19.7. Drivers and Restraints - Impact Analysis
- 19.8. Country Level Analysis & Forecast
- 19.8.1. GCC Countries Market Analysis
- 19.8.1.1. Introduction
- 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.1.2.1. By Drug Class
- 19.8.1.2.2. By Indication
- 19.8.1.2.3. By Pet Type
- 19.8.1.2.4. By Route of Administration
- 19.8.1.2.5. By Distribution Channel
- 19.8.2. Turkiye Market Analysis
- 19.8.2.1. Introduction
- 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.2.2.1. By Drug Class
- 19.8.2.2.2. By Indication
- 19.8.2.2.3. By Pet Type
- 19.8.2.2.4. By Route of Administration
- 19.8.2.2.5. By Distribution Channel
- 19.8.3. Egypt Market Analysis
- 19.8.3.1. Introduction
- 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.3.2.1. By Drug Class
- 19.8.3.2.2. By Indication
- 19.8.3.2.3. By Pet Type
- 19.8.3.2.4. By Route of Administration
- 19.8.3.2.5. By Distribution Channel
- 19.8.4. Israel Market Analysis
- 19.8.4.1. Introduction
- 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.4.2.1. By Drug Class
- 19.8.4.2.2. By Indication
- 19.8.4.2.3. By Pet Type
- 19.8.4.2.4. By Route of Administration
- 19.8.4.2.5. By Distribution Channel
- 19.8.5. South Africa Market Analysis
- 19.8.5.1. Introduction
- 19.8.5.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.5.2.1. By Drug Class
- 19.8.5.2.2. By Indication
- 19.8.5.2.3. By Pet Type
- 19.8.5.2.4. By Route of Administration
- 19.8.5.2.5. By Distribution Channel
- 19.8.6. Northern Africa Market Analysis
- 19.8.6.1. Introduction
- 19.8.6.2. Market Analysis and Forecast by Market Taxonomy
- 19.8.6.2.1. By Drug Class
- 19.8.6.2.2. By Indication
- 19.8.6.2.3. By Pet Type
- 19.8.6.2.4. By Route of Administration
- 19.8.6.2.5. By Distribution Channel
20. Market Structure Analysis
- 20.1. Market Analysis by Tier of Companies
- 20.2. Market Share Analysis of Top Players (%)
- 20.3. Market Presence Analysis
- 20.3.1. Regional Footprint of Players
- 20.3.2. Product Footprint of Players
- 20.3.3. Channel Footprint of Players
21. Competition Analysis
- 21.1. Competition Dashboard
- 21.2. Key Development Analysis
- 21.3. Branding and Promotional Strategies, By Key Players
- 21.4. Competition Deep Dive
- 21.4.1. Zoetis Animal Healthcare
- 21.4.1.1. Overview
- 21.4.1.2. Product Portfolio
- 21.4.1.3. Key Financials
- 21.4.1.4. Sales Footprint
- 21.4.1.5. SWOT Analysis
- 21.4.1.6. Strategy Overview
- 21.4.1.6.1. Marketing Strategies
- 21.4.1.6.2. Channel Strategies
- 21.4.1.6.3. Product Strategies
- 21.4.2. Merck and Co.Inc. (US)
- 21.4.2.1. Overview
- 21.4.2.2. Product Portfolio
- 21.4.2.3. Key Financials
- 21.4.2.4. Sales Footprint
- 21.4.2.5. SWOT Analysis
- 21.4.2.6. Strategy Overview
- 21.4.2.6.1. Marketing Strategies
- 21.4.2.6.2. Channel Strategies
- 21.4.2.6.3. Product Strategies
- 21.4.3. Boehringer Ingelheim GmbH
- 21.4.3.1. Overview
- 21.4.3.2. Product Portfolio
- 21.4.3.3. Key Financials
- 21.4.3.4. Sales Footprint
- 21.4.3.5. SWOT Analysis
- 21.4.3.6. Strategy Overview
- 21.4.3.6.1. Marketing Strategies
- 21.4.3.6.2. Channel Strategies
- 21.4.3.6.3. Product Strategies
- 21.4.4. Elanco Animal Health Incorporated
- 21.4.4.1. Overview
- 21.4.4.2. Product Portfolio
- 21.4.4.3. Key Financials
- 21.4.4.4. Sales Footprint
- 21.4.4.5. SWOT Analysis
- 21.4.4.6. Strategy Overview
- 21.4.4.6.1. Marketing Strategies
- 21.4.4.6.2. Channel Strategies
- 21.4.4.6.3. Product Strategies
- 21.4.5. Bayer AG
- 21.4.5.1. Overview
- 21.4.5.2. Product Portfolio
- 21.4.5.3. Key Financials
- 21.4.5.4. Sales Footprint
- 21.4.5.5. SWOT Analysis
- 21.4.5.6. Strategy Overview
- 21.4.5.6.1. Marketing Strategies
- 21.4.5.6.2. Channel Strategies
- 21.4.5.6.3. Product Strategies
- 21.4.6. Vetoquinol S.A.
- 21.4.6.1. Overview
- 21.4.6.2. Product Portfolio
- 21.4.6.3. Key Financials
- 21.4.6.4. Sales Footprint
- 21.4.6.5. SWOT Analysis
- 21.4.6.6. Strategy Overview
- 21.4.6.6.1. Marketing Strategies
- 21.4.6.6.2. Channel Strategies
- 21.4.6.6.3. Product Strategies
- 21.4.7. Dechra Pharmaceuticals PLC
- 21.4.7.1. Overview
- 21.4.7.2. Product Portfolio
- 21.4.7.3. Key Financials
- 21.4.7.4. Sales Footprint
- 21.4.7.5. SWOT Analysis
- 21.4.7.6. Strategy Overview
- 21.4.7.6.1. Marketing Strategies
- 21.4.7.6.2. Channel Strategies
- 21.4.7.6.3. Product Strategies
- 21.4.8. Virbac SA
- 21.4.8.1. Overview
- 21.4.8.2. Product Portfolio
- 21.4.8.3. Key Financials
- 21.4.8.4. Sales Footprint
- 21.4.8.5. SWOT Analysis
- 21.4.8.6. Strategy Overview
- 21.4.8.6.1. Marketing Strategies
- 21.4.8.6.2. Channel Strategies
- 21.4.8.6.3. Product Strategies
- 21.4.9. IDEXX Laboratories, Inc.
- 21.4.9.1. Overview
- 21.4.9.2. Product Portfolio
- 21.4.9.3. Key Financials
- 21.4.9.4. Sales Footprint
- 21.4.9.5. SWOT Analysis
- 21.4.9.6. Strategy Overview
- 21.4.9.6.1. Marketing Strategies
- 21.4.9.6.2. Channel Strategies
- 21.4.9.6.3. Product Strategies
- 21.4.10. Ceva Sante Animale
- 21.4.10.1. Overview
- 21.4.10.2. Product Portfolio
- 21.4.10.3. Key Financials
- 21.4.10.4. Sales Footprint
- 21.4.10.5. SWOT Analysis
- 21.4.10.6. Strategy Overview
- 21.4.10.6.1. Marketing Strategies
- 21.4.10.6.2. Channel Strategies
- 21.4.10.6.3. Product Strategies
- 21.4.11. Kindred Biosciences, Inc.
- 21.4.11.1. Overview
- 21.4.11.2. Product Portfolio
- 21.4.11.3. Key Financials
- 21.4.11.4. Sales Footprint
- 21.4.11.5. SWOT Analysis
- 21.4.11.6. Strategy Overview
- 21.4.11.6.1. Marketing Strategies
- 21.4.11.6.2. Channel Strategies
- 21.4.11.6.3. Product Strategies
- 21.4.12. Phirbo Animal Health
- 21.4.12.1. Overview
- 21.4.12.2. Product Portfolio
- 21.4.12.3. Key Financials
- 21.4.12.4. Sales Footprint
- 21.4.12.5. SWOT Analysis
- 21.4.12.6. Strategy Overview
- 21.4.12.6.1. Marketing Strategies
- 21.4.12.6.2. Channel Strategies
- 21.4.12.6.3. Product Strategies
- 21.4.13. Norbrook Laboratories Limited
- 21.4.13.1. Overview
- 21.4.13.2. Product Portfolio
- 21.4.13.3. Key Financials
- 21.4.13.4. Sales Footprint
- 21.4.13.5. SWOT Analysis
- 21.4.13.6. Strategy Overview
- 21.4.13.6.1. Marketing Strategies
- 21.4.13.6.2. Channel Strategies
- 21.4.13.6.3. Product Strategies
- 21.4.14. Vetiquinol SA
- 21.4.14.1. Overview
- 21.4.14.2. Product Portfolio
- 21.4.14.3. Key Financials
- 21.4.14.4. Sales Footprint
- 21.4.14.5. SWOT Analysis
- 21.4.14.6. Strategy Overview
- 21.4.14.6.1. Marketing Strategies
- 21.4.14.6.2. Channel Strategies
- 21.4.14.6.3. Product Strategies
- 21.4.15. Neogen Corporation
- 21.4.15.1. Overview
- 21.4.15.2. Product Portfolio
- 21.4.15.3. Key Financials
- 21.4.15.4. Sales Footprint
- 21.4.15.5. SWOT Analysis
- 21.4.15.6. Strategy Overview
- 21.4.15.6.1. Marketing Strategies
- 21.4.15.6.2. Channel Strategies
- 21.4.15.6.3. Product Strategies
- 21.4.16. PetIQ, Inc.
- 21.4.16.1. Overview
- 21.4.16.2. Product Portfolio
- 21.4.16.3. Key Financials
- 21.4.16.4. Sales Footprint
- 21.4.16.5. SWOT Analysis
- 21.4.16.6. Strategy Overview
- 21.4.16.6.1. Marketing Strategies
- 21.4.16.6.2. Channel Strategies
- 21.4.16.6.3. Product Strategies
- 21.4.17. Huvepharma AD
- 21.4.17.1. Overview
- 21.4.17.2. Product Portfolio
- 21.4.17.3. Key Financials
- 21.4.17.4. Sales Footprint
- 21.4.17.5. SWOT Analysis
- 21.4.17.6. Strategy Overview
- 21.4.17.6.1. Marketing Strategies
- 21.4.17.6.2. Channel Strategies
- 21.4.17.6.3. Product Strategies
- 21.4.18. Chanelle Pharma Group Limited
- 21.4.18.1. Overview
- 21.4.18.2. Product Portfolio
- 21.4.18.3. Key Financials
- 21.4.18.4. Sales Footprint
- 21.4.18.5. SWOT Analysis
- 21.4.18.6. Strategy Overview
- 21.4.18.6.1. Marketing Strategies
- 21.4.18.6.2. Channel Strategies
- 21.4.18.6.3. Product Strategies
- 21.4.19. Kepro
- 21.4.19.1. Overview
- 21.4.19.2. Product Portfolio
- 21.4.19.3. Key Financials
- 21.4.19.4. Sales Footprint
- 21.4.19.5. SWOT Analysis
- 21.4.19.6. Strategy Overview
- 21.4.19.6.1. Marketing Strategies
- 21.4.19.6.2. Channel Strategies
- 21.4.19.6.3. Product Strategies
- 21.4.20. Biogenesis Bago
- 21.4.20.1. Overview
- 21.4.20.2. Product Portfolio
- 21.4.20.3. Key Financials
- 21.4.20.4. Sales Footprint
- 21.4.20.5. SWOT Analysis
- 21.4.20.6. Strategy Overview
- 21.4.20.6.1. Marketing Strategies
- 21.4.20.6.2. Channel Strategies
- 21.4.20.6.3. Product Strategies
22. Assumptions and Acronyms Used
23. Research Methodology